載入中
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
前收盤價
US$2.13
−US$0.01 · -0.47%
盤中時間採用ET。市場資料可能有所延遲。
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
日內區間
目前US$2.13
52週區間
目前US$2.13
盤中時間採用ET。市場資料可能有所延遲。
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
日內區間
目前US$2.13
52週區間
目前US$2.13
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.49億 USD | 7489萬 USD | 7134.8萬 USD | 6520.6萬 USD | 5531.2萬 USD |
| 銷貨成本 | 7684.9萬 USD | 2072.9萬 USD | 1964.3萬 USD | 1548.3萬 USD | 1165.3萬 USD |
| 毛利 | 7230.8萬 USD | 5416.1萬 USD | 5170.5萬 USD | 4972.3萬 USD | 4365.9萬 USD |
| 研究與開發 | 658.4萬 USD | 1277.1萬 USD | 951.5萬 USD | 933.6萬 USD | 792.3萬 USD |
| 銷售、一般及管理費用 | 9716萬 USD | 7595.3萬 USD | 7274.4萬 USD | 7549.8萬 USD | 6330萬 USD |
| 營業費用 | 1.04億 USD | 8872.4萬 USD | 8225.9萬 USD | 8483.4萬 USD | 7122.3萬 USD |
| 利息收入 | — | — | 2.4萬 USD | — | — |
| 利息支出 | 841.5萬 USD | 728.6萬 USD | 542.4萬 USD | 360萬 USD | 330萬 USD |
| 折舊和攤銷 | 346.5萬 USD | 207.3萬 USD | 200.6萬 USD | 164.8萬 USD | 106萬 USD |
| 營業利益 | −3143.6萬 USD | −3456.3萬 USD | −3055.4萬 USD | −3511.1萬 USD | −2756.4萬 USD |
| 淨利 | −3899.8萬 USD | −4370.8萬 USD | −3018.9萬 USD | −3715.9萬 USD | −3119.3萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.00
上漲空間 134.74%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI300.04萬0.00%2.3兆 USD0.03%US$381.94+0.63%
AdvisorShares Psychedelics ETFPSIL182.89萬3.90%4685.29萬 USD1.84%US$21.765+3.69%
Vanguard Extended Market ETFVXF136.03萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC19.21萬0.01%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM19萬0.16%1.17億 USD0.73%US$15.9402+0.25%
Invesco NASDAQ Future Gen 200 ETFQQQS8.99萬0.40%2275.83萬 USD0.20%US$42.145+1.39%Vanguard Morningstar Total Stock Market ETFVTIAdvisorShares Psychedelics ETFPSILVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco NASDAQ Future Gen 200 ETFQQQSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
